Skip to main content

Merit Medical Launches the basixALPHA™ Inflation Device

Written by Customer Service on . Posted in Public Companies.

Ergonomic device provides fast inflation to streamline angioplasty procedures

SOUTH JORDAN, Utah, Nov. 28, 2022 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced U.S. commercial release of the basixALPHA™ Inflation Device.

The basixALPHA is the latest addition to the Merit inflation device portfolio. Products include analog and digital devices with low- and high-pressure capacity for inflation, deflation, and measurement of pressures in angioplasty balloons. Merit’s commitment to excellence in inflation device technology has resulted in decades of industry leadership. More than 10 million procedures have been completed using Merit inflation devices worldwide.

The new ergonomic device is designed for one-handed preparation and fast inflation with minimal exertion to streamline angioplasty procedures. Angioplasty, a type of percutaneous coronary intervention (PCI), is used to open narrowed or blocked arteries. Opening blocked arteries facilitates blood flow to the heart, minimizing damage. More than 1.2 million coronary angioplasty procedures are performed each year within the US.1

Learn more about the basixALPHA Inflation Device

“As a leader in inflation device technology, Merit understands that inflation devices serve as staples in the cath lab,” said Fred P. Lampropoulos, Merit Medical’s Chairman and CEO. “To provide physicians with an improved device, we listened to their feedback and innovated the basixALPHA—a technology that delivers fast inflation when needed most. It fits well within our robust portfolio of inventive yet reliable inflation device technologies, helping to improve the physician experience and patient outcomes around the globe.”

1. Medical News Today. 2019. “What to Know About Angioplasty.” https://www.medicalnewstoday.com/articles/327154

ABOUT MERIT MEDICAL Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling in excess of 600 individuals. Merit employs approximately 6,500 people worldwide.

TRADEMARKS Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc. and its subsidiaries in the United States and other jurisdictions.

CONTACTS

PR/Media Inquiries 
Sarah Comstock 
Merit Medical 
+1-801-432-2864 | sarah.comstock@merit.com

INVESTOR INQUIRIES 
Mike Piccinino, CFA, IRC 
Westwicke – ICR 
+1-443-213-0509 | mike.piccinino@westwicke.com 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.